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Abstract: Uterine myomas, the most common benign, solid, pelvic tumors in women, occur 
in 20%–40% of women in their reproductive years and form the most common indication for 
hysterectomy. Various factors affect the choice of the best treatment modality for a given patient. 
Asymptomatic myomas may be managed by reassurance and careful follow up. Medical therapy 
should be tried as a first line of treatment for symptomatic myomas, while surgical treatment 
should be reserved only for appropriate indications. Hysterectomy has its place in myoma 
management in its definitiveness. However, myomectomy, rather than hysterectomy, should be 
performed when subsequent childbearing is a consideration. Preoperative gonadotropin-releasing 
hormone analog treatment before myomectomy decreases the size and vascularity of the myoma 
but may render the capsule more fibrous and difficult to resect. Uterine artery embolization is an 
effective standard alternative for women with large symptomatic myomas who are poor surgi-
cal risks or wish to avoid major surgery. Its effects on future fertility need further evaluation in 
larger studies. Serial follow-up without surgery for growth and/or development of symptoms 
is advisable for asymptomatic women, particularly those approaching menopause. The present 
article is incorporated with multiple clear clinical photographs and simplified elaboration of 
the available management options for these tumors of uterine smooth muscle to facilitate clear 
understanding.
Keywords: myomectomy, uterine artery embolization, pelvic tumor, hysterectomy, GnRH, 
leiomyoma
Introduction
Fibroids are the most common benign uterine tumors, present in 20%–25% of women 
at reproductive age. Hysterectomy has been the most common treatment modality for 
symptomatic fibroids in the past. Based on data from 1990 to 1997, the presence of 
uterine fibroids formed the main indication for hysterectomy in the United States.1 
Myomectomy, the removal of fibroids surgically without hysterectomy, is the second 
most common surgical procedure for this condition.2 Despite the frequency with which 
fibroids are diagnosed and treated, there remains considerable uncertainty and contro-
versy among clinicians and women regarding the best way to manage them.3
The treatment modalities for uterine myomas may include expectant management, 
medical therapy, conventional surgical options, and newer and less invasive approaches. 
Age, parity, childbearing aspirations, extent and severity of symptoms, size, number and 
location of myomas, associated medical conditions, the risk of malignancy, proximity 
to menopause, and the desire for uterine preservation are some of the factors affecting 
the choice of therapeutic approach.4 Hence, the treatment should be individualized. International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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It must be recognized that all conservative management 
options allow the possibility for new leiomyomas to form, 
and preexisting small or undetected leiomyomas may exhibit 
significant growth, necessitating another treatment. The risk 
of recurrence must be balanced against the potential benefits 
of uterus sparing procedures, such as lower morbidity and 
retention of fertility.4 If malignancy is suspected, the treat-
ment must be surgical. The present article attempts to review 
the conventional and newer management options for uterine 
leiomyomas.
Expectant management
Asymptomatic women with leiomyoma of the uterus of less 
than 12 weeks size may be suitable candidates for expect-
ant management, especially those approaching menopause. 
However, an enlarged uterus may rarely cause significant 
compression of ureters that could compromise renal function. 
Piscitelli et al demonstrated ureteral dilatation in 56% patients 
with uterine size of 12 weeks or more, but no dilatation in 
those with uterine size less than 12 weeks.5 Women eligible 
for expectant management may report for follow-up every 
3–6 months where a detailed history and clinical examina-
tion is carried out to note the uterine size and rate of growth 
of the tumor.
Medical therapy
Various medications, both hormonal and nonhormonal, 
have been tried to control the symptoms produced by 
fibroids. Most medical therapies cause a significant but 
temporary reduction in myoma size and improve symptoms 
in most cases. These interventions may prepare the patient 
for surgery and in some cases render surgery unneces-
sary if, in the interim, the patient enters menopause.6 For 
reproductive purposes the effect of medical therapy is less 
obvious as the myomas tend to regrow on discontinuation 
of therapy.
Antifibrinolytics
Tranexamic acid, a synthetic derivative of lysine, exerts 
its antifibrinolytic effect through a reversible blockade of 
lysine-binding sites on plasminogen molecules, thus inhibit-
ing the activation of plasminogen to plasmin, which in turn 
is responsible for fibrin degradation. It has been used as a 
first-line nonhormonal therapy for heavy bleeding associated 
with uterine fibroids and dysfunctional uterine bleeding.6 It 
was approved for use for heavy menstrual bleeding by the 
United States Food and Drug Administration (FDA) in 2009. 
Prolonged treatment may theoretically increase the risk of 
deep vein thrombosis; most studies reveal the incidence of 
thrombosis in women treated with this agent to be similar to 
that in untreated cases.6
Nonsteroidal anti-inflammatory  
drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective 
in reducing dysmenorrhea and heavy menstrual losses by act-
ing as antagonists of prostaglandins, the agents that stimulate 
uterine contractility resulting in pain. Aspirin, ibuprofen, and 
naproxen are effective for dysmenorrhea. However, long-term 
use of these agents may produce gastric ulcers and gastro-
intestinal bleeding. Peura suggests that over use of NSAIDs 
contributes to gastrointestinal adverse effects and anemia by 
inhibiting the cyclooxygenase-1 enzyme.7
Oral contraceptive pills
These drugs are often used to control menorrhagia and dys-
menorrhea. However, as myomas are estrogen dependent, 
they may exhibit an increase in size with combined pills. 
For some women, the benefits of hormonal contraception 
outweigh the risk of this adverse affect.
Progestogens
Progestational agents are thought to produce a hypoestrogenic 
effect by inhibiting gonadotropin secretion and suppressing 
ovarian function, apart from exerting a direct anti-estrogenic 
effect at the cellular level. However, recent evidence that the 
antiprogesterone mifepristone decreases myoma size raises 
concerns about this mechanism.8 Moreover, the beneficial 
effects of these agents are transient. Asoprisnil, an orally 
active selective progesterone receptor modulator (SPRM) 
is being studied for management of symptomatic uterine 
leiomyomata, as it suppresses both the duration and inten-
sity of menstrual bleeding in a dose-dependent manner. Its 
use is associated with a statistically significant reduction 
(91%) in frequency and intensity of uterine bleeding in these 
women.9 The exact mechanism of action of this agent is 
not discernible, but a downregulation of collagen synthesis 
through upregulation of extracellular matrix metalloprotei-
nase inducer is proposed.10 The SPRMs offer the advantages 
of progesterone antagonism without their adverse effects.6 
However, a Phase III clinical trial evaluating the long-term 
(the proposed duration of the study was initially 2 years) 
safety of this drug in daily oral doses of 10 and 25 mg had 
to be discontinued prematurely due to changes detected in 
the endometrial samples. The endometrial changes reverted 
after discontinuation of the drug.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
233
Uterine myomas and their management
Danazol
Danazol, a synthetic isoxazole derivative chemically related 
to 17-ethinyl testosterone, creates a high androgen and low 
estrogen environment resulting in the wasting of endome-
trium and shrinkage of fibroids. Despite its reported benefits, 
various undesirable side effects are associated with its use; 
for example, acne, hirsutism, weight gain, irritability, mus-
culoskeletal pain, hot flushes, and breast atrophy. Danazol 
has been reported to be an effective therapy to shrink fibroids 
and control their symptoms.6 The anti-estrogenic effect of 
the agent is the probable mechanism of its efficacy in fibroid 
management. Patient compliance could be an issue, and a 
cautious dosing may help overcome the unpleasant adverse 
effects. However, there is no reliable evidence from random-
ized controlled trials (RCTs) regarding the benefits and/or 
harms of use of this drug for treating uterine myomas.11
Levonorgestrel intrauterine  
device
Use of a levonorgestrel intrauterine device (LNG-IUD) has 
been shown to be associated with a reduction in the menstrual 
blood loss in women with uterine myomas. However, reports 
on its effect on the size of uterine myoma and the uterus as a 
whole are conflicting.   Jindabenjerd et al reported a significant 
reduction in total myoma volume and average uterine size and 
a marked reduction in menstrual blood loss, though bleeding 
disturbances may occur in about 68% women with its use.12 
Murat Naki et al reported a menstrual-loss reduction of 60% 
and 35% at the end of 6 months and 2 years, respectively, but 
did not find any alteration in the myoma and uterine size after 
treatment with a LNG-IUD.13 Women with large myomas may 
also have more frequent spontaneous expulsion of this device. 
The device therefore may be more suitable for an undistorted 
uterine cavity and a uterine size of less than 12 weeks.6
Gonadotropin-releasing hormone  
analogs
Gonadotropin-releasing hormone analogs (GnRHa) have 
also been used successfully to achieve hypoestrogenism 
both as a primary means of conservative therapy for myo-
mas and as an adjunct to myomectomy. Their effects are 
transient, and the myomas usually return to pretherapy 
size within a few months of discontinuation.14 The reduc-
tion in myoma volume by preoperative GnRHa therapy 
may facilitate a hysteroscopic resection of a submucous 
myoma with less blood loss, although the tissue planes tend 
to become more fibrotic and adherent after this therapy.15 
The amenorrhea induced by preoperative GnRHa therapy 
may help in building up hemoglobin levels, thus enabling 
presurgical blood donation for subsequent autotransfusion. 
Menopausal symptoms, osteoporosis, and pelvic pain are 
some of the adverse effects of this therapy, and a hormonal 
add-back, if given, may negate the beneficial effects on 
myoma size.16 Danazol administration has been tried after 
6 months of GnRHa therapy in an effort to prolong the 
therapeutic effects of GnRHa. The bone mineral content 
that is substantially reduced during GnRHa treatment is 
reported to significantly improve with danazol, though 
a rebound of uterine volume due to its antiprogesterone 
effect is a possibility.17 In perimenopausal women, however, 
a short-term GnRHa therapy may eliminate the need for 
surgery. Hysterectomy may become technically easier and 
quicker after pretreatment with GnRHa. With the reduc-
tion in uterine size, a greater number of women posted for 
hysterectomy may be able to undergo a vaginal rather than 
an abdominal procedure. It also reduces blood loss and 
rate of vertical abdominal incisions at surgery. Lynesterol 
does not offer any advantage over GnRHa therapy prior to 
surgery for uterine myomas.18
Several add-back regimes have been tried in women 
using GnRHa in an effort to reduce the effects of estrogen 
deficiency. These include tibolone, raloxifene, progestogens 
alone, estrogens alone, and a combination of estrogens and 
progestogens. However, a hormonal add-back bears the risk of 
increase in size and quantity of myomas. Tibolone has a neu-
tral effect on myoma volume, and typical doses of raloxifene 
have no influence on its growth. Hence, if postmenopausal 
women with myomas need therapy to control symptoms, 
tibolone and raloxifene may be more suitable.19 Besides, 
tibolone has also been shown to reverse the deleterious effect 
on cognition that is caused by leuprolide acetate depot. Its 
addition improves mood and quality of life in women who 
receive GnRHa for symptomatic uterine myomas.20
Aromatase inhibitors
Recently, letrozole, a nonsteroidal aromatase inhibitor com-
monly used in anovulatory infertility in the follicular phase 
has been suggested to have a potential therapeutic role in 
treatment of leiomyomas.21 Aromatase, a member of the 
cytochrome p450 superfamily, is a microsomal enyzyme that 
catalyses conversion of androgens to estrogen. In leiomyoma, 
both aromatase and 17β-hydroxysteroid dehydrogenase 
type 1 enzymes are overexpressed in comparison with normal 
myometrium.22 Inhibition of aromatase enzyme by letrozole 
would block this conversion and hence result in an hypoestro-
genic environment. As the growth of leiomyoma is positively International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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correlated to circulating estrogen levels, the hypoestrogenic 
milieu would be inhibitory to myoma growth.
Literature on the role of aromatase inhibitors in leio-
myoma uterus is limited and comprises mainly a few 
case reports. Varelas et al reported a 55.7% reduction in 
  leiomyoma volume and 22.9% reduction in total uterine 
volume in their study using anastrazole 1 mg daily for three 
cycles.22 Mohammed et al used letrozole 2.5 mg per day for 
12 weeks and found total myoma volume reduction of 45.6% 
with no significant change in the hormonal milieu.23 Rapid 
onset of action and avoidance of initial gonadotropin flare 
with an aromatase inhibitor may be advantageous for man-
agement of women who wish to avoid surgical intervention 
or in whom surgery is contraindicated. Aromatase inhibitors 
have been found to be as effective as GnRHa, with fewer side 
effects. However, lack of knowledge of the effects of body 
mass index on the efficacy of these agents, sparse data on 
subsequent reproductive outcome, and absence of long-term 
follow-up data currently restricts the use of these agents to 
women without infertility.
Mifepristone
Since exposure to estrogen and progesterone promotes the 
growth of uterine leiomyomas, treatment with a well studied 
antiprogestin, mifepristone, has been evaluated. The effect of 
this agent on follicular development, ovulation, endometerial 
development, and function is dependent on the dose and tim-
ing of exposure; the agent is currently approved for medical 
abortion. Short-term administration of low doses of 2–5 mg 
per day to normal cycling women result in anovulation and 
inhibition of menstruation in over 90% of menstrual cycles.24 
The long-term administration of 100 mg/day of mifepris-
tone may induce ovarian acyclicity and relief of   pelvic pain 
in women with endometriosis.25 Since endometriosis and 
fibroids share ovarian steroid dependency, mifepristone 
may exhibit inhibitory effect on myoma growth. Engman 
et al treated 30 women with leiomyoma uterus with 50 mg 
mifepristone for 3 months prior to surgery and found a 28% 
reduction in the leiomyoma volume compared with 6% for 
the placebo group.26 Mifepristone may represent a viable 
alternative to GnRHa for use in the preoperative application. 
Moreover, if the safety of long-term, low-dose mifepristone is 
established, perimenopausal women with large, symptomatic 
fibroids may be able to take this medication until menopause, 
when the myoma typically regresses. Consequently, it would 
yield major savings in cost and morbidity in view of the 
large number of hysterectomies done for leiomyomata in 
perimenopausal women. In addition, younger women with 
large leiomyomata who wish to retain their fertility may also 
benefit from chronic low-dose mifepristone, until the time 
that they wish to conceive.
CDB-2914
CDB-2914, an antiprogestin, given in daily doses of 10–20 mg 
for three cycles, has been reported to reduce fibroid size by 
36%, compared with a 6% increase with placebo.27 Of the 18 
women included in the only available study evaluating the 
role of this drug on myoma volume, patients received a 10 or 
20 mg dose of CDB-2914 daily or an inactive placebo. Only 
one woman (out of a total of six) in the study experienced 
menstrual bleeding during treatment with CDB-2914. Low 
estrogen levels were evident in the CDB-2914 group and it 
may be safer than other medical therapies for myoma due to 
the drug’s relatively specific antiprogesterone effect.27
Magnetic resonance-guided focused 
ultrasound surgery
In October 2004, the FDA approved magnetic resonance 
imaging (MRI)-guided focused ultrasound treatment of uterine 
fibroids in humans, which is being sold as ExAblate in the 
United States. The rise in temperature of the tissue receiving 
the high intensity focused ultrasound and the resultant protein 
denaturation and irreversible cell damage form the basis of this 
treatment modality.28 The method uses multiple exposures of 
high intensity focused ultrasound energy on the target fibroid 
to raise the tissue temperature to levels high enough to destroy 
it. The MRI not only allows a three-dimensional precise view 
of the target tissue, but also provides quantitative, real-time 
thermal images of the treated area. Most myomas appear as 
sharply marginated areas of low to intermediate signal intensity 
while one-third may have inhomogenous areas of high signal 
intensity (resulting from hemorrhage, degeneration, edema, or 
high cellular content) on T2-weighted images. Symptomatic 
women who are otherwise free of any contraindication to MRI 
and desiring a noninvasive therapeutic outpatient option for 
myoma are suitable candidates for this modality. A reduction of 
up to 98% in myoma volume and symptoms has been reported 
with this noninvasive treatment for symptomatic myomas.29 
However, the efficacy of magnetic resonance-guided focused 
ultrasound surgery (MRgFUS) correlates with signal intensity 
of T2-weighted magnetic resonance images. Those with low 
signal intensity on pretreatment images are more likely to 
shrink than those with high signal intensity.30 The larger the 
nonperfused volume immediately after treatment, the greater 
the volume reduction and symptom relief. Thus, Type 1(low 
intensity) and 2 (intermediate intensity) fibroids are suitable International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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for this treatment, while Type 3 (high intensity) myomas are 
not.31
Women having a myoma volume of more than 500 cm3 
may be pretreated with a GnRHa for 3 months in an attempt 
to reduce the size to improve the efficacy of thermal ablation.32 
It has been suggested that the use of GnRHa potentiates the 
thermal effects of MRgFUS, particularly in women with 
uterine diameter of 10 cm or more.33 Small myoma size, 
intramural location, fewer number, and T2 hypodensity 
are important predictors of treatment success.34 Symptomatic 
improvement lasts for over 2 years, and 16%–20% women 
may need additional therapy.35 Although there is paucity of 
large RCTs between MRgFUS and uterine artery embolization 
(UAE), initial reports suggest MRgFUS is comparable in 
efficacy, safety, and cost effectiveness to UAE.36
Uterine artery embolization
This procedure, first described for management of myomas in 
1995, attempts to limit growth by limiting the blood   supply. 
Polyvinyl alcohol particles of 500 µm size are passed through 
a fluoroscopically guided transarterial catheter inserted in the 
common femoral artery to selectively occlude the arteries 
supplying the myoma. This short interventional radiologic 
procedure requires a short hospital stay and is recommended 
for large symptomatic myomas in women who do not wish 
or are poor candidates for major surgery. Goodwin et al 
reported the long-term outcomes from the FIBROID (Fibroid 
Registry for Outcomes Data) registry based on a 3-year study 
of 2112 patients who underwent uterine artery embolization 
for symptomatic leiomyomas.37 The procedure was found to 
be associated with improvement in quality of life and a subse-
quent need for hysterectomy, myomectomy, or repeat uterine 
artery embolization in 9.79%, 2.82%, and 1.83% patients, 
respectively. Persistent ischemic pain, postembolization 
fever, severe postembolization syndrome, pyometra, sepsis, 
hysterectomy, and even deaths have been reported after the 
procedure.38 Ovarian failure may ensue in 1%–2% patients, 
though successful pregnancies too have been reported after 
embolization.39
A retrospective cohort study showed that UAE has much 
fewer serious adverse effects than hysterectomy (odds ratio 
0.25) and similar rates of satisfaction.40 In this study, 86% 
women treated with UAE would recommend the procedure 
to a friend in comparison to 70% of those who underwent 
hysterectomy. A review of two RCTs comparing UAE with 
abdominal hysterectomy in 234 women found that UAE 
reduced fibroid-related menstrual blood loss by 85% and the 
dominant fibroid volume by 30%–46%. It also   significantly 
reduced the length of hospital stay at the time of the 
  procedure but was associated with more minor complications, 
unscheduled hospital visits, and higher readmission rates 
than   hysterectomy.41 It may be advisable to withhold GnRHa 
therapy if UAE is planned, as the GnRHa-related constriction 
of the uterine vessels may cause technical difficulty at UAE. 
The procedure should preferably be done after 12 weeks of 
stoppage of GnRHa therapy.
Surgical management
Careful observation is suitable for most myomas, as most of 
them produce no symptoms, are confined to the pelvis, and 
are rarely malignant.42 Surgical options may be considered 
in cases of abnormal uterine bleeding that is unresponsive 
to conservative management, a high degree of suspicion of 
pelvic malignancy, growth of myoma after menopause, dis-
tortion of endometrial cavity or tubal obstruction in infertile 
women and in those with recurrent pregnancy losses, pain, 
or pressure symptoms interfering with quality of life, and 
anemia secondary to chronic uterine blood loss.
Abdominal myomectomy
Myomectomy has been the procedure of choice for symp-
tomatic myomas in women desiring retention of uterus and 
often for a solitary pedunculated myoma. However, the 
number of tumors is no limitation for this procedure. Since 
submucous myomas have been implicated in the etiology 
of infertility and recurrent pregnancy loss, myomectomy is 
recommended by some before gonadotrophin stimulation for 
in vitro fertilization and also in women with large myomas 
that may interfere with oocyte retrieval.4 Nevertheless, this 
continues to be a controversial area, and the removal of an 
otherwise asymptomatic large myoma which does not distort 
the endometrial cavity may not be a reasonable proposi-
tion in these cases. The procedure may be considered in 
patients with large myomas, especially those with a distorted 
endometrial cavity and in those with unexplained in vitro 
fertilization failures.17
A thorough preoperative evaluation is advisable prior 
to myomectomy. Women with menstrual irregularities and 
those with risk of endometrial pathology require endometrial 
histologic evaluation before myomectomy, particularly if 
aged more than 35 years.4 Hysteroscopy, if available, may 
be useful at the time of endometrial sampling in diagnosing 
intrauterine pathology like polyps, foreign bodies, or forgot-
ten intrauterine devices. In our opinion, definitive surgery 
should be deferred for 4–6 weeks after hysteroscopy so as to 
minimize the chances of disseminated infection.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Optimization of hematological status of the patient prior 
to surgery is of paramount importance. The anemic woman 
should be pretreated with GnRHa or progestational agents 
to produce amenorrhea. Stored autologous or donated blood 
should be arranged for surgery.
The procedure can be carried out by laparoscopy or 
laparotomy. A meta-analysis of six RCTs and 576 patients 
suggests that laparoscopic myomectomy is associated with 
less hemoglobin drop, reduced operative blood loss, more 
patients fully recuperated at day 15, diminished operative 
pain, and fewer overall complications, but longer operation 
time.43 The study concluded that if performed by suitably 
specialized surgeons in selected patients, laparoscopic myo-
mectomy is a better choice than open surgery.   However, 
the quality of uterine repair would influence the risk of 
uterine rupture during a subsequent pregnancy event. 
Hemorrhage and adhesion formation continue to be other 
areas of concern after myomectomy. The therapeutic choice 
between a myomectomy, hysterectomy, or other surgical 
options should be based on age and the desire for fertility 
preservation.
The blood loss at surgery correlates with uterine size, 
weight of myomas removed, and the operating time.   Various 
pharmacologic vasoconstricting agents and mechanical 
vascular occlusion techniques have been tried to minimize 
surgical blood loss. A meta-analysis of 10 RCTs and 531 
participants analyzed the various hemostatic measures 
used – intramyometrial vasopressin and analogs, intravenous 
oxytocin, vaginal misoprostol, peri-cervical tourniquet, 
chemical dissection with sodium-2-mercaptoethane sulfonate 
(mesna), intramyometrial bupivacaine plus epinephrine, 
tranexamic acid, and enucleation of myoma by morcellation 
while it is attached to the uterus.44 All these measures except 
oxytocin and enucleation by morcellation were found to 
result in reduced bleeding at myomectomy, while oxytocin 
and morcellation were not found to affect the operative 
blood loss.
The isthmic myomas may be a class apart among the 
myomas as far as growth dynamics are concerned. They 
are reported to be subjected to uterine peristaltic waves in 
opposite directions during different phases of the menstrual 
cycle, thus resulting in a tangential growth.45 This may pose 
difficulty in apprehending the extent and correct anatomic 
relations at the time of surgery. Figure 1 is a clinical intraop-
erative photograph taken during myomectomy of an anterior 
isthmic fibroid and a normal-sized body of the uterus. The 
patient was a 21-year-old nulliparous woman presenting with 
a lump in the abdomen and infertility.
Adequate exposure, hemostasis, careful handling of 
reproductive tissues, and adhesion prevention are some of the 
general principles of abdominal myomectomy. The operative 
morbidity associated with this procedure has not been shown 
to be any higher than that of hysterectomy.46 When extensive 
dissection of the myometrium has been necessary during myo-
mectomy, irrespective of the actual opening of the endometrial 
cavity, a subsequent cesarean delivery is advisable.
Hysteroscopic myomectomy
This procedure is indicated for abnormal bleeding, history 
of pregnancy loss, infertility, and pain, while suspicion of 
endometrial malignancy, inability to distend the cavity or 
circumnavigate the lesion, and tumor extension deep into the 
myometrium are the chief contraindications. Around 20% of 
women will need additional therapy within 10 years of this 
procedure, mainly due to incomplete removal or new myoma 
growth.4 The European Society of Hysteroscopy classifies 
submucous myomas according to the extent of myometrial 
invasion into four categories to help the hysteroscopist plan 
the surgical approach.47 Category T:O includes all pedun-
culated submucus myomas. Submucus myomas extending 
less than 50% into the myometrium are classified as T:I, 
while those with greater than 50% penetration are classified 
as T:II. Category T:O and T:I can be removed hysteroscopi-
cally by a surgeon with modest previous experience, while 
Category T:II myomas should be resected abdominally, and 
hysteroscopic resection should be reserved for highly skilled 
hysteroscopic surgeons.
Figure 1 A clinical intraoperative photograph taken during myomectomy of an 
anterior isthmic fibroid and a normal-sized body of the uterus.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Reduction in myoma volume by preoperative GnRHa 
therapy may facilitate a hysteroscopic resection of a sub-
mucus myoma with less blood loss, although the tissue 
planes tend to become more fibrotic, adherent, and less clear 
after this treatment.15 Figure 2 is a hysteroscopic view of a 
  submucus myoma arising from the uterine fundus.
vaginal myomectomy
Large myomas arising from the uterine body may fill the 
vagina and result in intermenstrual bleeding, unhealthy dis-
charge, or urinary retention. Most of these can be enucleated 
per vaginum and the stalk ligated. Rarely, they may form the 
etiological basis of a uterine inversion, particularly the large 
ones arising from the fundus. Figure 3 is an intraoperative 
clinical photograph of ipsilateral inversion of the right side of 
the fundus consequent upon a large stalked myoma reaching 
up to the introitus and filling the vagina.
Laparoscopic/robotically assisted 
laparoscopic myomectomy
Superficial subserous or pedunculated myomas are best suited 
for laparoscopic or robotically assisted laparoscopic removal. 
Their removal is effected by either morcellation, utilization 
of a colpotomy incision, or myolysis. Laparoscopic myomec-
tomy in infertile women with intramural myomas offers com-
parable results to laparotomy, and the pregnancy rates tend 
to be affected by other associated infertility factors.48 Uterine 
rupture during pregnancy after laparoscopic myomectomy has 
been attributed to inadequate reconstruction of myometrium 
during surgery. All women wishing to undergo myomectomy 
should be willing for a   hysterectomy, if need be. The finding of 
a diffuse leiomyomatosis in a woman posted for myomectomy 
is not uncommon. For those who desire conception, a delay 
of 4–6 months before attempting pregnancy is recommended 
after myomectomy to allow for myometrial healing.
Hysterectomy
Hysterectomy is the most common major gynecological surgical 
procedure performed in women, and 33.5% of these are done 
for myomas.4 Depending on the size, number, and location 
of the tumors, the skill of the surgeon and the availability of 
instruments, the open technique, laparoscopy, and vaginal 
route are the other ports of access to the myoma-bearing 
uterus. Hysterectomy has been the surgical procedure of choice 
for myomas when childbearing considerations have been 
fulfilled or when there is reasonable likelihood of   malignancy. 
Figure 4 is a clinical photograph of   leiomyosarcoma arising 
Figure 2 A pedunculated fundal submucus myoma at hysteroscopy.
Figure 3 Partial (right-sided) inversion of uterine fundus caused by a large stalked 
myoma arising from the fundus.
Figure  4  A  clinical  photograph  of  leiomyosarcoma  arising  in  a  leiomyomatous 
uterus as seen at hysterectomy.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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in a leiomyomatous uterus of a 36-year-old parous woman 
presenting with menometrorrhagia. Hysterectomy is associated 
with a high degree of patient satisfaction, eliminates the need 
for progestational agents and enables the woman to take 
unopposed estrogen therapy without many concerns. Recently, 
nondescent vaginal hysterectomy of a myomatous uterus has 
generated appreciable interest. However, the procedure may 
be ideally suited only up to 12 weeks uterine size. Procedures 
like morcellation, bisection, coring, or wedge resection of the 
uterus may be successful in skilled hands if the uterine size 
exceeds 12 weeks. Besides the myoma/uterine size, presence 
of adhesions, previous pelvic/lower abdominal surgeries, 
and nonavailability of surgeon skilled in the procedure are 
other contraindications for nondescent vaginal hysterectomy. 
Figure 5 shows a nondescent vaginal hysterectomy of a 
myomatous uterus in progress. Adhesions and anatomic 
distortions of the uterus pose an increased risk of damage to 
the urinary and intestinal tract at hysterectomy. Hysterectomy 
for broad ligament myoma has been reported to carry a ureteric 
injury risk of 0.4/1000.49 False broad ligament myomas tend 
to push the ureter laterally and posteriorly, in contrast to true 
broad ligament fibroids where the ureter is medial to the 
myoma. Figures 6 and 7 are intraoperative photographs of 
true and false broad ligament myomas taken at hysterectomy. 
Knowledge of the precise location and origin of the myoma 
as well as skill and experience of the surgeon is of immense 
importance in order to avoid inadvertent injuries to the urinary 
tract. Similarly, large cervical myomas pose difficulties as well 
as increase the risk of urinary tract injury during application 
of clamps on the Macenrodt’s and uterosacral ligaments. 
Figure 8 shows a normal sized uterine body sitting atop a large 
posterior cervical myoma after hysterectomy. Conservation 
of cervix at hysterectomy has been proposed to reduce the 
risk of subsequent vaginal vault prolapse and to maintain 
good sexual function.50 A supracervical hysterectomy is also 
associated with a decreased risk of urinary tract injury and 
requires less operating time. However, the need for cervical 
screening for cancer of the cervix in women undergoing 
supracervical hysterectomy is maintained. Around 61.4% 
women over 45 years of age undergoing hysterectomy for   
Figure 5 A nondescent vaginal hysterectomy of a myomatous uterus in progress.
Figure 6 A false broad ligament myoma as seen at laparotomy.
Figure 7 Intraoperative clinical photograph of enucleation of a true broad ligament 
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myoma also undergo concomitant bilateral ophorectomy.51 The 
opinion regarding preservation of apparently healthy ovaries 
continues to be divided. At least for women less than 45 years 
of age, the ovaries should be spared.
Myolysis
Various forms of myolysis – bipolar, cryo, radiofrequency, 
laparoscopic, and MRI-guided laser, have been tried as con-
servative alternatives to myomectomy in women   wishing 
uterine preservation.52,53 Carbon dioxide laser has been used to 
directly vaporize small myomas at laparotomy, while medium 
and large myomas are excised. Improved hemostasis and 
greater precision at removal appear to be the chief advantage, 
but the technique has not been tested in a larger series of 
patients. Some submucous myomas have been successfully 
treated by Nd:YAG (neodymium-doped yttrium aluminium 
garnet) laser, which devascularizes the myoma; however, 
incomplete removal may be an issue of concern at times.
Uterine artery ligation
This procedure attempts to limit the blood supply to the uterus 
by a vaginal or laparoscopic ligation of the uterine artery. 
The procedure shares its underlying principle with UAE but 
is relatively easier to perform. Akinola et al found the uterine 
artery ligation to be as effective as UAE, while Hald et al found 
it to be less effective in direct comparison to UAE.54,55 The pro-
cedure has also been tried in association with myomectomy and 
is reportedly associated with less introperative blood loss com-
pared with myomectomy carried out without it.56 The procedure 
may reduce postpartum blood loss and minimize the need for 
future surgery in pregnant women with uterine myomas, who 
are undergoing cesarean section.57 Subsequent fertility does 
not appear to be adversely affected by the procedure. A com-
bination of uterine artery occlusion (UAO) and simultaneous 
blockage of anastomosis between uterine and ovarian vessels 
may be better than UAO alone in terms of long-term symptom 
control and reintervention rates.58 However, women undergo-
ing simultaneous utero-ovarian anastomosis vessel occlusion 
are at greater risk of a significant increase in serum follicle-
stimulating hormone levels at the first month after surgery, thus 
reflecting a diminished ovarian function.59
Conclusion
Asymptomatic myomas can be managed by reassurance and 
careful follow up. Medical therapy should be tried as a first-line 
of treatment for symptomatic myomas, while surgical treatment 
should be reserved only for appropriate indications. Hysterec-
tomy has its place in myoma management in its definitiveness. 
However, myomectomy, rather than hysterectomy, should be 
performed when subsequent childbearing is a consideration. 
Preoperative GnRH-analog treatment before myomectomy 
decreases the size and vascularity of the myoma but may render 
the capsule more fibrous and difficult to resect. Uterine artery 
embolization is an effective standard alternative for women 
with large symptomatic myomas who are poor surgical risks or 
wish to avoid major surgery. Its effects on future fertility need 
further evaluation in larger studies. Serial follow-up without 
surgery for growth and/or development of symptoms is advis-
able for asymptomatic women, particularly those approaching 
menopause. MRgFUS represents an alternative modality of 
conservative treatment of uterine myomas and is comparable 
to UAE for efficacy, safety, and cost.
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